Hot Pursuit     21-Jan-25
Venus Remedies jumps after renewing EU GMP certification
Venues remedies rallied 5.30% to Rs 310.95 after the company successfully renewed its European good manufacturing practices (GMP) certification by infarmed, the national health authority of Medicines and Health products in Portugal.
The company’s manufacturing facility covers, Cephalosporin, Carbapenem and Oncology (liquid& lyophilized injectable) formulations.

The company had received its first EU GMP certification in 2007. It has consistently maintained a robust presence in the European market for over 15 years. As one of the leading exporters of Meropenem outside India and with multiple marketing aithoriszations across Europe.

Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation.

The company’s consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24.

Previous News
  Venus Remedies consolidated net profit declines 99.34% in the March 2022 quarter
 ( Results - Announcements 28-May-22   08:09 )
  Venus Remedies consolidated net profit declines 76.98% in the September 2022 quarter
 ( Results - Announcements 13-Nov-22   09:01 )
  Venus Remedies reports standalone net profit of Rs 4.53 crore in the March 2017 quarter
 ( Results - Announcements 02-Jun-17   17:51 )
  Venus Remedies jumps as investigational drug secures QIDP tag from USFDA
 ( Hot Pursuit - 17-Apr-25   10:23 )
  Venus Remedies to conduct board meeting
 ( Corporate News - 03-Aug-17   10:50 )
  Venus Remedies net profit rises 7.29% in the December 2013 quarter
 ( Results - Announcements 12-Feb-14   08:30 )
  G G Engineering Ltd leads losers in 'B' group
 ( Hot Pursuit - 18-Apr-22   14:45 )
  Venus Remedies postpones board meeting
 ( Corporate News - 19-Jul-24   10:59 )
  Venus Remedies reports consolidated net loss of Rs 4.07 crore in the June 2019 quarter
 ( Results - Announcements 14-Aug-19   15:44 )
  Venus Remedies Ltd Spikes 5.64%
 ( Hot Pursuit - 31-May-23   09:30 )
  Venus Remedies receives market authorization for Bleomycin 15,000 IU in UK
 ( Corporate News - 26-Oct-23   10:00 )
Other Stories
  HDFC Life Q4 PAT climbs 16% YoY to Rs 476 cr
  17-Apr-25   17:32
  Infosys Q4 PAT rises 3% QoQ to Rs 7,038 cr; declares dividend of Rs 22/sh
  17-Apr-25   17:25
  HDFC AMC rises after Q4 PAT jumps 18% YoY to Rs 639 cr; declares final dividend of Rs 90/sh
  17-Apr-25   17:11
  Sonata Software drops amid lower Q4 revenue guidance
  17-Apr-25   15:54
  Home First Finance gains after raising Rs 1,250 crore
  17-Apr-25   15:07
  Sonata Software Ltd leads losers in 'A' group
  17-Apr-25   15:00
  Lupin gets EIR from USFDA for Nagpur facility
  17-Apr-25   15:00
  AGI Infra's housing project in Punjab gets RERA registration
  17-Apr-25   15:00
  Alkem Labs' subsidiary concludes acquisition of 100% stake in Bombay Ortho
  17-Apr-25   14:49
  Vikram Aroma Ltd leads losers in 'B' group
  17-Apr-25   14:45
Back Top